trientine dihydrochloride

Triethylenetetramine dihydrochloride (commonly known as trientine dihydrochloride) is a small molecule copper(II)-selective chelating agent. Structurally analogous to the linear polyamines spermidine and spermine, it acts by binding to divalent copper(II) ions to form a stable complex, which is subsequently excreted through the kidneys. Originally developed by Merck and approved under the brand name Syprine in 1985, and later by Univar Solutions under the brand name Cufence in 2019, it is primarily indicated as a second-line treatment for Wilson's disease in patients who are intolerant to D-penicillamine. Additionally, Protemix Corporation has investigated triethylenetetramine dihydrochloride in Phase 1 clinical trials as a comparator reference drug for the treatment of diabetic complications, including heart failure in patients with type 2 diabetes.

Brand names

CufenceSyprineClovique

Other names

triethylenetetramine dihydrochloridetrientine hydrochloridetriethylenetetraminetrientineTETAtrien2,2,2-tetramine